...

 
Cannvas.Me
Sign Up For Free
Emerald Health Services majority owned subsidiary Nemus Biosciences (NMUS) has developed its lead product to treat glaucoma using cannabinoids. 

The patented drug formulation of THC is altered into a proprietary formulation tilted NB1111 so that it is easier to deliver to the human eye. 

Glaucoma is caused by eye pressure on the optic nerve that can result in a blockage between the brain and the retina. THC has been shown to prevent continued damage from Glaucoma, however current methods of ingestion, such as smoking, are often an issue because of the amount that is needed. 

Source: https://www.equities.com/news/nemus-biosciences-is-working-with-cannabinoids-to-treat-glaucoma

This article is now marked as read.

Was this article helpful?

Review this article to help us continue creating and sharing relevant content.

Please note it may take up to two business days for reviews to be validated and published.

Reviews

Review this article to help us continue creating and sharing relevant content.

Write Review

Would you like to
make this review public?

Please disable your ad blocker to avoid issues using social plugins on Cannvas.Me. Thanks.
Close